SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994.
The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.
SV Life Sciences Announces Important Senior Leadership Promotion - 13 January 2014
BOSTON, MA, SAN FRANCISCO, CA, LONDON, UK (January 13, 2014): SV Life Sciences ("SVLS"), a leading international life sciences venture capital firm, today announced the appointments of Eugene Hill as Chairman, Paul LaViolette as Managing Partner and Chief Operating Officer, Tom Flynn as Managing Partner and Hamish Cameron as Operating Partner. James Garvey, who has served in senior leadership roles since 1995, most recently as Chairman, will become the firm's Chairman Emeritus.
Rempex Pharmacuticals Exit - December, 2013
SV Life Sciences notes that on 04 December 2013 – The Medicines Company (NASDAQ: MDCO) entered in to a definitive agreement to purchase Rempex Pharmaceuticals for an upfront payment price of $140m and has agreed to pay Rempex equity holders milestone payments subsequent to closing.